BACKGROUND Glomus Jugulare tumors are benign but locally aggressive ones that represent a therapeutic challenge. Previous studies about the use of Gamma Knife Radiosurgery (GRS) in those tumors have documented good results that needed larger number of patients and longer follow up periods to be confirmed. MATERIAL AND METHODS Between August 2001 and December 2017, 70 patients with glomus jugulare tumors were treated at the Gamma Knife Center, Cairo. They were 46 females and 24 males. The mean age was 48 years (16–71 years). Nineteen of these patients were previously operated, 5 were partially embolized, 3 underwent embolization and subsequent surgery and 43 had gamma knife as their primary treatment. Volume-staged gamma knife radiosurgery was used in 10 patients and single-session in 60 patients, with a total of 86 sessions. The mean target volume was 12.7 cm3 (range 0.2 to 34.5 cm3). The mean tumor volume was 15.5 cm3 (range 0.2 to 105 cm3). The mean prescription dose was 14.5 Gy (range 12 to 18 Gy). RESULTS The mean follow up period was 60 months (range 18 to 206 months), and by the time of the data analysis, two of the patients were dead (66 and 24 months after GK treatment). The tumor control was 98.6% (69/70). Thirty-two tumors became smaller and 37 were unchanged. The symptoms improved in 36 patients, were stable in 32 patients, and worsened in 2 patients who developed a transient facial palsy and worsened hearing. Symptomatic improvement began before any reduction in tumor volume could be detected, where the mean time to clinical improvement was 7 months whereas the mean time to tumor shrinkage was 18 months. CONCLUSION This study about the long term follow up of the GKR for the intracranial glomus jugulare tumors confirmed that this is a highly effective and safe treatment. This data shows that the clinical improvement is not correlated with the radiological volume reduction.

中文翻译：

---

P14.67 伽马刀放射外科治疗颅内颈静脉球瘤的长期结果

背景技术颈静脉球瘤是良性的但具有局部侵袭性的肿瘤，代表了治疗挑战。先前关于在这些肿瘤中使用伽玛刀放射外科 (GRS) 的研究已经记录了良好的结果，需要更多的患者和更长的随访时间才能得到证实。材料与方法 2001 年 8 月至 2017 年 12 月，70 名颈静脉球瘤患者在开罗伽玛刀中心接受治疗。他们是46名女性和24名男性。平均年龄为 48 岁（16-71 岁）。这些患者中有 19 名之前接受过手术，5 名部分栓塞，3 名接受了栓塞和后续手术，43 名以伽玛刀为主要治疗方法。体积分期伽玛刀放射外科治疗 10 例，单次治疗 60 例，共 86 次。平均目标体积为 12.7 cm3（范围 0.2 至 34.5 cm3）。平均肿瘤体积为 15.5 cm3（范围 0.2 至 105 cm3）。平均处方剂量为 14.5 Gy（范围 12 至 18 Gy）。结果平均随访时间为 60 个月（范围 18 至 206 个月），到数据分析时，两名患者死亡（GK 治疗后 66 个月和 24 个月）。肿瘤控制率为 98.6% (69/70)。32 个肿瘤变小，37 个没有变化。36 名患者的症状得到改善，32 名患者的症状稳定，2 名患者的症状恶化，出现短暂性面瘫和听力恶化。在检测到肿瘤体积缩小之前，症状的改善就开始了，临床改善的平均时间为 7 个月，而肿瘤缩小的平均时间为 18 个月。结论 本研究对颅内颈静脉球瘤的GKR长期随访证实，这是一种高效、安全的治疗方法。该数据显示临床改善与放射量减少无关。